Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

 Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

Shots:
  •  Keytruda sold $1.67Bn, 90% Y-o-Y, narrowly beating Opdivo’s $1.63Bn in Q2’18
  •  Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% reduction in death in NSCLC patient vs chemo
  • Above combination is showing immense attraction from Physicians despite of pending FDA approval
Click here to read full press release/ article | Ref: Merck | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post